http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics (CYTK) and The ALS Association Renew Partnership to Advance the Fight Against ALS
-
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
-
Cytokinetics (CYTK) Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at ACC
-
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Jou
-
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
-
Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
-
Cytokinetics Reports First Quarter 2021 Financial Results
-
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
-
Cytokinetics to Hold Annual Meeting of Stockholders
-
Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics to Announce First Quarter Results on May 6, 2021
-
Cytokinetics (CYTK) Announces Preclinical Data for CK-3773274 Presented at American Chemical Society Meeting
-
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting
-
Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference
-
Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics (CYTK) Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at ACC.21
-
Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
-
Cytokinetics to Participate in Upcoming Investor Conferences
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
-
Cytokinetics Reports Fourth Quarter 2020 Financial Results
-
Cytokinetics (CYTK) Adds Muna Bhanji to Board
-
Cytokinetics Names Muna Bhanji to Board of Directors
-
Cytokinetics to Announce Fourth Quarter Results on February 25, 2021
-
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
-
Cytokinetics (CYTK) Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
-
Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
-
Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
-
Cytokinetics (CYTK) Regains European Rights to Omecamtiv Mecarbil
-
Cytokinetics Regains European Rights to Omecamtiv Mecarbil
-
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
-
Cytokinetics (CYTK) Announces Progression of REDWOOD-HCM to Cohort 2
-
Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2
-
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
-
Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum
-
Cytokinetics to Participate in Upcoming Investor Conferences
-
Cytokinetics (CYTK) Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen (AMGN)
-
Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
-
Cytokinetics Names Nancy Wysenski to Board of Directors
-
Cytokinetics (CYTK) Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA
-
Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020
-
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
-
Cytokinetics (CYTK) Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in NEJM

